HF Advisory Group LLC Decreases Holdings in Pfizer Inc. $PFE

Key Points

• HF Advisory Group LLC cut its Pfizer stake by 40.3% in Q4, selling 60,205 shares and leaving 89,146 shares valued at about $2.22 million per its Form 13F filing.
• Institutional ownership remains high at 68.36%, with major holders such as State Street, Northern Trust, Legal & General and Amundi increasing their Pfizer positions in recent quarters.
• Analyst sentiment is mixed with a consensus "Hold" and an average target of $28.14, as price targets and ratings range from underweight/underperform $25 to outperform $30 among recent reports.

HF Advisory Group LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 40.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 89,146 shares of the biopharmaceutical company's stock after selling 60,205 shares during the period. HF Advisory Group LLC's holdings in Pfizer were worth $2,220,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. State Street Corp increased its holdings in Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock worth $7,620,747,000 after buying an additional 2,786,098 shares during the last quarter. Northern Trust Corp increased its holdings in Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock worth $1,631,225,000 after buying an additional 869,175 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock worth $1,255,860,000 after buying an additional 897,786 shares during the last quarter. Legal & General Group Plc increased its holdings in Pfizer by 8.6% during the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock worth $1,063,565,000 after buying an additional 3,296,415 shares during the last quarter. Finally, Amundi increased its holdings in Pfizer by 10.8% during the third quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company's stock worth $1,096,380,000 after buying an additional 4,043,413 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. Royal Bank Of Canada initiated coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an "underperform" rating and a $25.00 target price for the company. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Morgan Stanley lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a research note on Friday. BMO Capital Markets reiterated an "outperform" rating and issued a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. Finally, Barclays initiated coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an "underweight" rating and a $25.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $28.14.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.91 on Friday. The company has a 50 day moving average of $27.20 and a 200 day moving average of $25.94. The stock has a market cap of $152.99 billion, a P/E ratio of 19.78 and a beta of 0.43. Pfizer Inc. has a 12 month low of $21.28 and a 12 month high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the business posted $0.63 earnings per share. Pfizer's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Morgan Stanley raised its price target to $28 and kept an "equal weight" rating, implying modest upside and signaling some confidence in near-term fundamentals. Morgan Stanley raises PFE price target (Benzinga)
• Positive Sentiment: MarketWatch noted a recent intraday uptick (but continued underperformance versus the broader market), which can attract short-term buyers looking for mean-reversion after pullbacks. Pfizer Inc. stock rises Wednesday (MarketWatch)
• Neutral Sentiment: Zacks flagged Pfizer as a "trending" stock, meaning elevated retail/institutional attention — this can increase volatility but doesn’t by itself indicate direction. Pfizer is a trending stock (Zacks)
• Neutral Sentiment: Coverage pieces (Yahoo/MSN) are re-examining Q4 earnings, one-year performance and valuation after a strong one‑year gain; these narratives shape whether investors view PFE as fairly valued or still a buy. Is Pfizer Offering Value (Yahoo) Q4 earnings highs and lows (MSN)
• Neutral Sentiment: Pfizer announced its virtual Annual Meeting on April 23; routine corporate governance items can temper short-term trading but are unlikely to change fundamentals. Annual meeting webcast (BusinessWire)
• Neutral Sentiment: Industry research on the biopharmaceutical CXO market cites Pfizer among large players navigating outsourcing and supply-chain trends — a background macro theme that could help longer-term margins but is not an immediate catalyst. Biopharmaceutical CXO market report (Yahoo/GlobeNewswire)
• Negative Sentiment: Bank of America cut its price target to $26 and moved to "neutral," signaling downside risk and adding selling pressure from model-driven desks. Bank of America lowers PFE PT (Benzinga)
• Negative Sentiment: Zacks ran a comparative piece showing AbbVie (ABBV) pulling ahead on strong growth from Skyrizi and Rinvoq, underscoring competitive headwinds in immunology that could pressure Pfizer’s growth multiple. AbbVie vs Pfizer growth comparison (Zacks)
• Negative Sentiment: Coverage explaining why Pfizer tumbled earlier in the week highlights mixed near-term signals (analyst downgrades, rotation to other healthcare names), which can prolong weak sentiment even after small positive data points. Why Pfizer stock tumbled (Yahoo)

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.